Full Length Research Paper
References
|
Akkiz H (2021). Implications of the novel mutations in the SARS?CoV?2 genome for transmission, disease severity, and the vaccine development. Frontiers in Medicine 8:636532. |
|
|
Ali F, Kasry A, Amin M (2021). The new SARS?CoV?2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant. Medicine in Drug Discovery |
|
|
Baj J, Karaku?a-Juchnowicz H, Teresi?ski G, Buszewicz G, Ciesielka M, Sitarz R, Forma A, Karaku?a K, Flieger W, Portincasa P, Maciejewski R (2020). COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge. Journal of Clinical Medicine 9(6):1753. |
|
|
Bajaj A, Purohit HJ (2020). Understanding SARS-CoV-2: Genetic diversity, transmission and cure in Human. Indian Journal of Microbiology 60:398-401. |
|
|
Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L (2021). Novel SARS?CoV?2 variants: the pandemics within the pandemic. Clinical Microbiology and Infection 27(8):1109-1117. S1198?743X(21)00262?7. |
|
|
Brant AC, Tian W, Majerciak V, Yang W, Zheng ZM (2021). SARS-CoV-2: from its discovery to genome structure, transcription, and replication. Cell and Bioscience 11(1):1-17. |
|
|
Chakraborty C, Bhattacharya M, Sharma AR (2021). Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S?glycoprotein, infectivity, re?infectivity, immune escape and vaccines activity. Reviews in Medical Virology 32(2):e2270. |
|
|
Chakraborty C, Sharma RA, Bhattacharya M, Agoramoorthy G, Lee SS (2021). The current second wave and COVID?19 vaccination status in India. Brain, Behaviour and Immunity 96:1-4. |
|
|
Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S (2020). Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes and Infectinons 9(1):221-236. |
|
|
Chen J, Wang R, Wang M, Wei GW (2020). Mutations Strengthened SARS-CoV-2 Infectivity. Journal of Molecular Biology 432(19):5212-5226. |
|
|
Chen RE, Zhang X, Case JB, Winkler ES, Liu Y , VanBlargan LA, Liu J, Errico JM, Xie X, Suryadevara?N, Gilchuk P, Zost SJ, Tahan S, Droit L, Turner JS, Kim W, Schmitz AJ, Thapa M, Wang D, Boon ACM, Presti RM, O'Halloran JA, Kim?AHJ, Deepak? P, Pinto D, Fremont?DH, Crowe Jr JE, Corti D, Virgin?HW, Ellebedy AH, Shi P, Diamond? MS (2021) Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nature Medicine 27(4):717-726. |
|
|
Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, Rakshit P, Singh S, Abraham P, Panda S, Team N (2021). SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. Microorganisms 9(7):1542. |
|
|
Collier DA, De Marco A, Ferreira IATM, Meng B, Datir R, Walls AC, Kemp SA, Bassi J, Pinto D, Fregni CS, Bianchi S, Tortorici MA, Bowen J, Culap K, Jaconi S, Cameroni E, Snell G, Pizzuto MS, Pellanda AF, Garzoni C, Riva A, Elmer A, Kingston N, Graves B, Mccoy LE, Smith KG, Bradley JR, Thaventhiran J, Ceron-Gutierrez L, Barcenas-Morales G, Virgin HW, Lanzavecchia A, Piccoli L, Doffinger R, Wills M, Veesler D, Corti D, Gupta RK (2021) Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 593:136-141. |
|
|
Conti P, Caraffa A, Gallenga CE, Kritas SK, Frydas I, Younes A, Di Emidio P, Tetè G, Pregliasco F, Ronconi G (2021). The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Journal of Biological Regulators and Homeostatic Agents 35(1):1-4. doi: 10.23812/21-3-E. |
|
|
Davidson AM, Wysocki J, Batlle D (2020). Interaction of SARS-CoV-2 and other coronavirus with ACE (angiotensin-converting enzyme)-2 as their main receptor: therapeutic implications. Hypertension 76(5):1339-1349. |
|
|
Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CA, Russell TW, Tully DC, Washburne AD, Wenseleers T (2021). Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England. Science 372(6538):eabg3055. |
|
|
Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-González A, Glasner DR, Reyes KR, Gliwa AS, Reddy NP, Sanchez San Martin C, Federman S, Cheng J, Balcerek J, Taylor J, Streithorst JA, Miller S, Sreekumar B, Chen PY, Schulze-Gahmen U, Taha TY, Hayashi JM, Simoneau CR, Kumar GR, McMahon S, Lidsky PV, Xiao Y, Hemarajata P, Green NM, Espinosa A, Kath C, Haw M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Frankino PA, Shivram H, Lareau LF, Wyman SK, Ott M, Andino R, Chiu CY (2021). Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 184(13):3426-3437.e8. |
|
|
ECDC (2021). Emergence of SARS?CoV?2 B.1.617 variants in India and situation in the EU/EEA. 2021:2?12. |
|
|
Graham C, Seow J, Huettner I, Khan H, Kouphou N, Acors S, Winstone H, Pickering S, Galao RP, Dupont L, Lista MJ, Jimenez-Guardeño JM, Laing AG, Wu Y, Joseph M, Muir L, van Gils MJ, Ng WM, Duyvesteyn HME, Zhao Y, Bowden TA, Shankar-Hari M, Rosa A, Cherepanov P, McCoy LE, Hayday AC, Neil SJD, Malim MH, Doores KJ (2021). Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity 54(6):1276-1289e6. |
|
|
Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, Hilton SK, Huddleston J, Eguia R, Crawford KHD, Dingens AS, Nargi RS, Sutton RE, Suryadevara N, Rothlauf PW, Liu Z, Whelan SPJ, Carnahan RH, Crowe JE, Bloom JD (2021). Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host and Microbe 29(1):44-57.e9 |
|
|
Guan Q, Sadykov M, Mfarrej S, Hala S, Naeem R, Nugmanova R, Al-Omari A, Salih S, Al Mutair A, Carr MJ, Hall WW, Arold ST, Pain A (2020). A genetic barcode of SARS-CoV-2 for monitoring global distribution of different clades during the COVID-19 pandemic. International Journal of Infectious Diseases 100:216-223. |
|
|
Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H (2004). Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology 203(2):631-637. |
|
|
Hartenian E, Nandakumar D, Lari A, Ly M, Tucker JM, Glaunsinger BA (2020). The molecular virology of coronaviruses. Journal of Biological Chemistry 295(37):12910-12934. |
|
|
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181(2):271-280.e8. |
|
|
Inzaule SC, Tessema SK, Kebede Y, Ouma AEO, Nkengasong JN (2021). Genomic-informed pathogen surveillance in Africa: opportunities and challenges. Lancet Infectious Diseases 21(9):e281-e289 |
|
|
Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Krammer F, Simon V, Martinez-Sobrido L, García-Sastre A, Schotsaert M (2021). SARS?CoV?2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe 2(7):e283-e284 |
|
|
Karki R, Pandya D, Elston RC, Ferlini C (2015). Defining, "mutation" and "polymorphism" in the era of personal genomics. BMC Medical Genomics 8:1-7. |
|
|
Khan A, Zia T, Suleman M, Khan T, Ali SS, Abbasi AA, Mohammad A, Wei DQ (2021). Higher infectivity of the SARS?CoV?2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data. Journal of Cellular Physiology 236(10):7045-7057 |
|
|
Klein S, Cortese M, Winter SL, Wachsmuth-Melm M, Neufeldt CJ, Cerikan B, Stanifer ML, Boulant S, Bartenschlager R, Chlanda P (2020). SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography. Nature Communications 11(1):5885. |
|
|
Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva TI; Sheffield COVID-19 Genomics Group, McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC, Saphire EO, Montefiori DC (2020). Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell 182(4):812-827. |
|
|
Koyama T, Weeraratne D, Snowdon JL, Parida L (2020). Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment. Pathogens 9(5):324. |
|
|
Kumar S (2021). Vaccines efficac y to SARS-CoV-2 variants require holistic knowledge of viral immunology and protein biochemistry. Human Vaccines & Immunotherapeutics 17(11):4128-4130. |
|
|
Lemey P, Hong SL, Hill V, Baele G, Poletto C, Colizza V, O'Toole A, McCrone JT, Andersen KG, Worobey M, Nelson MI, Rambaut A, Suchard MA (2020). Accommodating individual travel history and unsampled diversity in Bayesian phylogeographic inference of SARS-CoV-2. Nature Communications 11(1):5110. |
|
|
Li X, Wang W, Zhao X, Zai J, Zhao Q, Li Y, Chaillon A (2020). Transmission dynamics and evolutionary history of 2019-nCoV. Journal of Medical Virology 92(5):501-511. |
|
|
Liu DX, Fung TS, Chong KKL, Shukla A, Hilgenfeld R (2014). Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Research 109:97-109. |
|
|
Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, Cai H, Sarkar R, Chen W, Cutler M, Cooper D, Weaver SC, Muik A, Sahin U, Jansen KU, Xie X, Dormitzer PR, Shi PY (2021a). Neutralizing Activity of BNT162b2-Elicited Serum. The New England Journal of Medicine 384(15):1466-1468. |
|
|
Liu Y, Liu J, Xia H, Zhang X, Zou J, Fontes-Garfias CR, Weaver SC, Swanson KA, Cai H, Sarkar R, Chen W, Cutler M, Cooper D, Muik A, Sahin U, Jansen KU, Xie X, Dormitzer PR, Shi PY (2021b). BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. The New England Journal of Medicine 385(5):472-474. |
|
|
Livnat A (2013). Interaction-based evolution: how natural selection and nonrandom mutation work together. Biology Direct 8(1):1-53. |
|
|
Lohr B, Niemann D, Verheyen J (2021). Bamlanivimab treatment leads to rapid selection of immune escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient. Clinical Infectious Diseases 73(11):2144-2145. |
|
|
Lu L, Lycett S, Ashworth J, Mutapi F, Woolhouse M (2021). What are SARS-CoV-2 genomes from the WHO Africa region member states telling us? BMJ Global Health 6(1):e004408. |
|
|
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395(10224):565-574. |
|
|
Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW, Hennig BP, Kreuter M, Conrad C, Eils R (2020). SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. European Molecular Biology Organization Journal 39(10):e105114. |
|
|
Mansbach RA, Chakraborty S, Nguyen K, Montefiori DC, Korber B, Gnanakaran S (2021). The SARS?CoV?2 spike variant D614G favors an open conformational state. Science Advances 7(16):eabf3671. |
|
|
Maurier F, Beury D, Fle'chon L, Varre' JS, Touzet H, Goffard A, Hot D, Caboche S (2019). A complete protocol for whole-genome sequencing of virus from clinical samples: Application to coronavirus OC43. Virology 531:141-148. |
|
|
Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, Hou C, Wang H, Liu J, Yang D, Xu Y, Cao Z, Gao Z (2020). Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Critical Care 24(1):1-10. |
|
|
Nigeria Centre for Disease Control and Prevention (NCDC) (2021). Statement on Variants of SARS-COV-2 in Nigeria. |
|
|
Nonaka CKV, Franco MM, Gräf T, de Lorenzo Barcia CA, de Ávila Mendonça RN, de Sousa KAF, Neiva LMC, Fosenca V, Mendes AVA, de Aguiar RS, Giovanetti M, de Freitas Souza BS (2021). Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil. Emerging Infectious Diseases 27(5):1522-1524. |
|
|
O'Toole Á, Hill V (2021). Global Report of B.1.525 lineage. |
|
|
Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Communications 11(1):1620 |
|
|
Ozer EA, Simons LM, Adewumi OM, Fowotade AA, Omoruyi EC, Adeniji JA, Dean TJ, Zayas J, Bhimalli PP, Ash MK, Godzik A, Schneider JR, Mamede JI, Taiwo BO, Hultquist JF, Lorenzo-Redondo R (2021). Coincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria. medRxiv: the preprint server for health sciences, 2021.04.09.21255206. |
|
|
Paules CI, Marston HD, Fauci AS (2020). Coronavirus infections-more than just the common cold. Journal of the American Medical Association 323(8):707-708. |
|
|
Pereira F, Tosta S, Lima MM, Oliveira da Silva LR, Nardy VB, Gómez MKA, Lima JG, Fonseca V, de Oliveira T, Lourenço J, Alcantara Jr. LC, Giovanetti M, Leal A (2021). Genomic surveillance activities unveil the introduction of the SARS?CoV?2 B.1.525 variant of interest in Brazil: case report. Journal of Medical Virology 10.1002/jmv.27086 |
|
|
Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou J, Fontes-Garfias CR, Mirchandani D, Scharton D, Bilello JP, Ku Z, An Z, Kalveram B, Freiberg AN, Menachery VD, Xie X, Plante KS, Weaver SC, Shi P (2021). Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592(7852):116-121. |
|
|
Rahimi F, Abadi ATB (2021). Implications of the emergence of a new variant of SARS-CoV-2, VUI-202012/01. Archives of Medical Research 52(5):569-571. |
|
|
Rambaut A, Holmes EC, O'Toole A, Hill V, McCrone JT, Ruis C, du Plessis L, Pybus OG (2020a). A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature Microbiology 5(11):1403-1407. |
|
|
Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, Connor T, Peacock T, Robertson DL, Volz E (2020b). COVID-19 Genomics Consortium UK. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological.org. Posted December 16, 2020. Accessed January 3, 2021. |
|
|
Rodpothong P, Auewarakul P (2012). Viral evolution and transmission effectiveness. World Journal of Virology 1(5):131-134. |
|
|
Sanjuan R, Domingo-Calap P (2016). Mechanisms of viral mutation. Cellular and Molecular Life Sciences 73:4433-4448. |
|
|
Thakur V, Bhola S, Thakur P, Singh Patel SK., Kulshrestha S, Ratho RK, Kumar P (2021). Waves and variants of SARS CoV 2: understanding the causes and efect of the COVID 19 catastrophe. Infection 50:309-325 |
|
|
Vaidyanathan G (2021). Coronavirus variants are spreading in India-what scientists know so far. Nature 593(7859):321?322. |
|
|
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181(2):281-292. |
|
|
Wang H, Li X, Li T, Zhang S, Wang L, Wu X, Liu J (2020). The genetic sequence, origin, and diagnosis of SARS-CoV-2. European Journal of Clinical Microbiology and Infectious Diseases 39(9):1629-1635. |
|
|
Wolff G, Melia CE, Snijder EJ, Barcena M (2020). Double-membrane vesicles as platforms for viral replication. Trends in Microbiology 28(12):1022-1033. |
|
|
World Health Organization (WHO) (2020) Coronavirus disease (COVID-19) pandemic. |
|
|
World Health Organization (WHO) (2021). COVID?19 weekly epidemiological update. 2021:1?30. |
|
|
World Health Organization (WHO) (2022). |
|
|
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367(6483):1260-1263. |
|
|
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Luan ML, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ (2020). A new coronavirus associated with human respiratory disease in China. Nature 579:265-269. |
|
|
Xie? X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, Xia H, Swanson KA, Cutler M, Cooper D, Menachery VD, Weaver SC, Dormitzer PR, Shi P (2021). Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nature Medicine 27(4):620-621. |
|
|
Yadav PD, Gajanan N Sapkal, Priya Abraham, Raches Ella, Gururaj Deshpande, Patil DY, Nyayanit DA, Gupta N, Sahay RR, Shete AM, Panda S, Bhargava B, Mohan VK (2022). Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees. Clinical Infectious Diseases 74(2):366-368. |
|
|
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q (2020). Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367(6485):1444-1448. |
|
|
Zhao S, Lou J, Chong MK, Cao L, Zheng H, Chen Z, Chan RWY, Zee BCY, Chan PKS, Wang MH (2021). Inferring the Association between the Risk of COVID-19 Case Fatality and N501Y Substitution in SARS-CoV-2. Viruses 13(4):638. |
|
|
Zhao Z, Sokhansanj BA, Malhotra C, Zheng K, Rosen GL (2020). Genetic grouping of SARS-CoV-2 coronavirus sequences using informative subtype markers for pandemic spread visualization. PLoS Computational Biology 16(9):e1008269. |
|
|
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Jing Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270-273. |
|
|
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W (2020). China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine 382(8):727-733. |
|
|
Zou J, Xie X, Fontes?Garfias CR, Swanson KA, Kanevsky I, Tompkins K, Cutler M, Cooper D, Dormitzer PR, Shi PY (2021). The effect of SARS?CoV?2 D614G mutation on BNT162b2 vaccine?elicited neutralization. NPJ Vaccines. 6(1):44. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
